Biosensor for rapid detection of SARS-CoV-2 in real-world samples

The current COVID-19 pandemic has become a worldwide problem with more than 169 million people infected by May 2021. Here we demonstrate a unique technology, based on the quartz crystal microbalance method, for the rapid detection of SARS-CoV-2. This biosensor fulfils all of the many requirements fo...

Full description

Saved in:
Bibliographic Details
Published inProceedings of IEEE Sensors ... pp. 1 - 4
Main Authors Forinova, Michala, Pilipenco, Alina, Visova, Ivana, Kuncak, Jakub, Lynn, N. Scott, Yudin, Petr, Dostalek, Jakub, Honig, Vaclav, Palus, Martin, Maskova, Hana, Dycka, Filip, Sterba, Jan, Vrabcova, Marketa, Arnostova, Judita, Spasovova, Monika, Tung, Chao-Ping, Yang, An-Suei, Dejneka, Alexandr, Vaisocherova-Lisalova, Hana
Format Conference Proceeding
LanguageEnglish
Published IEEE 31.10.2021
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The current COVID-19 pandemic has become a worldwide problem with more than 169 million people infected by May 2021. Here we demonstrate a unique technology, based on the quartz crystal microbalance method, for the rapid detection of SARS-CoV-2. This biosensor fulfils all of the many requirements for the rapid detection of SARS-CoV-2 in complex samples. This is achieved by a tailored antifouling surface post-modified with antibodies against SARS-CoV-2 nucleocapsid protein (N). The A-QCM profits from absence of sample pre-treatment and utilizes the natural properties of N protein, which forms complexes with vRNA. Thanks to this, the clinically relevant LOD of 6.7×10 3 PFU/mL was reached using one-step detection assay. The A-QCM biosensor was also validated with clinical samples (i.e. nasopharyngeal swabs) with full agreement with qRT-PCR. The A-QCM biosensor was also utilized for the presence of SARS-CoV-2 in surface swabs in means of public transport.
ISSN:2168-9229
DOI:10.1109/SENSORS47087.2021.9639783